Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Author:
Affiliation:
1. Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm500627s
Reference37 articles.
1. The genetics of the p53 pathway, apoptosis and cancer therapy
2. Surfing the p53 network
3. p53 Mutations in Human Cancers
4. p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis
5. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy;Journal of Medicinal Chemistry;2023-12-07
2. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer;Current Medicinal Chemistry;2023-10
3. Small molecules targeting protein–protein interactions for cancer therapy;Acta Pharmaceutica Sinica B;2023-10
4. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06
5. Ubiquitin–proteasome system as a target for anticancer treatment—an update;Archives of Pharmacal Research;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3